Ad-hoc | 4 May 2004 13:12

STRATEC: Jump in earnings with significant increase in sales already in Q1-FY04

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Jump in earnings with significant increase in sales already in Q1-FY2004 Birkenfeld, May, 4, 2004 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard and in Gate-M, announces the results for the first quarter of 2004, ending on March 31, 2004, pursuant to Section 15 of the German Securities Trading Law (WpHG). STRATEC increased its earnings to EUR 0.507m (2003: EUR 5.124m). This results in undiluted earnings per share (EPS) amounting to EUR 0.15 (2003: EUR 0.02). These calculation is based on around 3.3 million shares. Sales was could be increased by 54.7% to EUR 7.298m (2003: 5.124m). The overall performance improved by 55.4% to EUR 8.643m (2003: 5.562m). Overview of Key Figures pursuant to IFRS (International Financial Reporting Standards): Key figures in 000s 01.01.-03.31.2004 01.01.-03.31.2003 Change Sales 7,928 5,124 +54.7% Overall performance 8,643 5,562 +55.4% EBITDA 1,070 354 +202.3% EBIT 863 156 +453.2% EBT 806 98 +722.4% Net income for the period 507 56 +805,4% At the end of the first quarter, STRATEC had 158 employees (2003: 142). end of ad-hoc-announcement (c)DGAP 04.05.2004 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Reasons for the significant increase in STRATEC’s earnings are the decline in fixed costs and in particular personnel costs in R&D, both positioned in the STRATEC business model (OEM). The more extensive interim report can be downloaded from our homepage from around 3 p.m. on May 18, 2004. About STRATEC Biomedical Systems AG STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. STRATEC is a publicly listed stock corporation. Shares in the company (WKN: 728900/ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestraße 37 D-75217 Birkenfeld Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 eMail: ir@stratec-biomedical.de ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München 041312 Mai 04